507 related articles for article (PubMed ID: 24187110)
1. Effectiveness and safety of tocilizumab: postmarketing surveillance of 7901 patients with rheumatoid arthritis in Japan.
Koike T; Harigai M; Inokuma S; Ishiguro N; Ryu J; Takeuchi T; Takei S; Tanaka Y; Sano Y; Yaguramaki H; Yamanaka H
J Rheumatol; 2014 Jan; 41(1):15-23. PubMed ID: 24187110
[TBL] [Abstract][Full Text] [Related]
2. Longterm Safety of Tocilizumab: Results from 3 Years of Followup Postmarketing Surveillance of 5573 Patients with Rheumatoid Arthritis in Japan.
Yamamoto K; Goto H; Hirao K; Nakajima A; Origasa H; Tanaka K; Tomobe M; Totsuka K
J Rheumatol; 2015 Aug; 42(8):1368-75. PubMed ID: 26034149
[TBL] [Abstract][Full Text] [Related]
3. Safety and effectiveness of subcutaneous tocilizumab in patients with rheumatoid arthritis in a real-world clinical setting.
Atsumi T; Fujio K; Yamaoka K; Tomobe M; Kuroyanagi K; Kameda H
Mod Rheumatol; 2018 Sep; 28(5):780-788. PubMed ID: 29251032
[TBL] [Abstract][Full Text] [Related]
4. Effectiveness and safety of tocilizumab in achieving clinical and functional remission, and sustaining efficacy in biologics-naive patients with rheumatoid arthritis: The FIRST Bio study.
Ishiguro N; Atsumi T; Harigai M; Mimori T; Nishimoto N; Sumida T; Takeuchi T; Tanaka Y; Nakasone A; Takagi N; Yamanaka H
Mod Rheumatol; 2017 Mar; 27(2):217-226. PubMed ID: 27414105
[TBL] [Abstract][Full Text] [Related]
5. Longterm safety and efficacy of tocilizumab in patients with rheumatoid arthritis: a cumulative analysis of up to 4.6 years of exposure.
Genovese MC; Rubbert-Roth A; Smolen JS; Kremer J; Khraishi M; Gómez-Reino J; Sebba A; Pilson R; Williams S; Van Vollenhoven R
J Rheumatol; 2013 Jun; 40(6):768-80. PubMed ID: 23457383
[TBL] [Abstract][Full Text] [Related]
6. Postmarketing surveillance of tocilizumab for rheumatoid arthritis in Japan: interim analysis of 3881 patients.
Koike T; Harigai M; Inokuma S; Ishiguro N; Ryu J; Takeuchi T; Takei S; Tanaka Y; Ito K; Yamanaka H
Ann Rheum Dis; 2011 Dec; 70(12):2148-51. PubMed ID: 21852254
[TBL] [Abstract][Full Text] [Related]
7. Clinical evaluation of tocilizumab for patients with active rheumatoid arthritis refractory to anti-TNF biologics: tocilizumab in combination with methotrexate.
Nakashima Y; Kondo M; Harada H; Horiuchi T; Ishinishi T; Jojima H; Kuroda K; Miyahara H; Nagamine R; Nakashima H; Otsuka T; Saikawa I; Shono E; Suematsu E; Tsuru T; Wada K; Iwamoto Y
Mod Rheumatol; 2010 Aug; 20(4):343-52. PubMed ID: 20480201
[TBL] [Abstract][Full Text] [Related]
8. Safety and effectiveness of adalimumab in Japanese rheumatoid arthritis patients: postmarketing surveillance report of the first 3,000 patients.
Koike T; Harigai M; Ishiguro N; Inokuma S; Takei S; Takeuchi T; Yamanaka H; Tanaka Y
Mod Rheumatol; 2012 Aug; 22(4):498-508. PubMed ID: 21993918
[TBL] [Abstract][Full Text] [Related]
9. Tocilizumab in systemic juvenile idiopathic arthritis in a real-world clinical setting: results from 1 year of postmarketing surveillance follow-up of 417 patients in Japan.
Yokota S; Itoh Y; Morio T; Origasa H; Sumitomo N; Tomobe M; Tanaka K; Minota S
Ann Rheum Dis; 2016 Sep; 75(9):1654-60. PubMed ID: 26644233
[TBL] [Abstract][Full Text] [Related]
10. ROUTINE-a prospective, multicentre, non-interventional, observational study to evaluate the safety and effectiveness of intravenous tocilizumab for the treatment of active rheumatoid arthritis in daily practice in Germany.
Iking-Konert C; von Hinüber U; Richter C; Schwenke H; Gürtler I; Kästner P; Klapperich B; Peters MA; Burmester GR
Rheumatology (Oxford); 2016 Apr; 55(4):624-35. PubMed ID: 26515959
[TBL] [Abstract][Full Text] [Related]
11. Tocilizumab in rheumatoid arthritis: a case study of safety evaluations of a large postmarketing data set from multiple data sources.
Curtis JR; Perez-Gutthann S; Suissa S; Napalkov P; Singh N; Thompson L; Porter-Brown B;
Semin Arthritis Rheum; 2015 Feb; 44(4):381-8. PubMed ID: 25300699
[TBL] [Abstract][Full Text] [Related]
12. Tocilizumab is clinically, functionally, and radiographically effective and safe either with or without low-dose methotrexate in active rheumatoid arthritis patients with inadequate responses to DMARDs and/or TNF inhibitors: a single-center retrospective cohort study (KEIO-TCZ study) at week 52.
Izumi K; Kaneko Y; Yasuoka H; Seta N; Kameda H; Kuwana M; Takeuchi T
Mod Rheumatol; 2015 Jan; 25(1):31-7. PubMed ID: 24684408
[TBL] [Abstract][Full Text] [Related]
13. Longterm safety and effectiveness of the anti-interleukin 6 receptor monoclonal antibody tocilizumab in patients with systemic juvenile idiopathic arthritis in Japan.
Yokota S; Imagawa T; Mori M; Miyamae T; Takei S; Iwata N; Umebayashi H; Murata T; Miyoshi M; Tomiita M; Nishimoto N; Kishimoto T
J Rheumatol; 2014 Apr; 41(4):759-67. PubMed ID: 24634205
[TBL] [Abstract][Full Text] [Related]
14. Importance of methotrexate therapy concomitant with tocilizumab treatment in achieving better clinical outcomes for rheumatoid arthritis patients with high disease activity: an observational cohort study.
Kojima T; Yabe Y; Kaneko A; Takahashi N; Funahashi K; Kato D; Hanabayashi M; Asai S; Hirabara S; Asai N; Hirano Y; Hayashi M; Miyake H; Kojima M; Ishiguro N
Rheumatology (Oxford); 2015 Jan; 54(1):113-20. PubMed ID: 25102861
[TBL] [Abstract][Full Text] [Related]
15. [Relationship of the clinical efficiency of tocilizumab therapy to the serum level of matrix metalloproteinase-3 in patients with rheumatoid arthritis].
Avdeeva AS; Aleksandrova EN; Novikov AA; Cherkasova MV; Panasyuk EY; Nasonov EL
Ter Arkh; 2013; 85(5):24-9. PubMed ID: 23819335
[TBL] [Abstract][Full Text] [Related]
16. Twenty-four-week clinical results of adalimumab therapy in Japanese patients with rheumatoid arthritis: retrospective analysis for the best use of adalimumab in daily practice.
Kaneko A; Hirano Y; Fujibayashi T; Hattori Y; Terabe K; Kojima T; Ishiguro N
Mod Rheumatol; 2013 May; 23(3):466-77. PubMed ID: 22895833
[TBL] [Abstract][Full Text] [Related]
17. Safety and effectiveness of adalimumab in Japanese rheumatoid arthritis patients: postmarketing surveillance report of 7740 patients.
Koike T; Harigai M; Ishiguro N; Inokuma S; Takei S; Takeuchi T; Yamanaka H; Haruna S; Ushida N; Kawana K; Tanaka Y
Mod Rheumatol; 2014 May; 24(3):390-8. PubMed ID: 24252049
[TBL] [Abstract][Full Text] [Related]
18. Postmarketing surveillance of the safety and effectiveness of etanercept in Japan.
Koike T; Harigai M; Inokuma S; Inoue K; Ishiguro N; Ryu J; Takeuchi T; Tanaka Y; Yamanaka H; Fujii K; Freundlich B; Suzukawa M
J Rheumatol; 2009 May; 36(5):898-906. PubMed ID: 19332630
[TBL] [Abstract][Full Text] [Related]
19. Tocilizumab efficacy and safety in rheumatoid arthritis patients after inadequate response to disease-modifying anti-rheumatic drugs oranti-tumor necrosis factor.
Abdulkader OAF; Qushmaq K; Aljishi F
Ann Saudi Med; 2016; 36(3):190-6. PubMed ID: 27236390
[TBL] [Abstract][Full Text] [Related]
20. Subset analysis of patients experiencing clinical events of a potentially immunogenic nature in the pivotal clinical trials of tocilizumab for rheumatoid arthritis: Evaluation of an antidrug antibody ELISA using clinical adverse event-driven immunogenicity testing.
Stubenrauch K; Wessels U; Birnboeck H; Ramirez F; Jahreis A; Schleypen J
Clin Ther; 2010 Aug; 32(9):1597-609. PubMed ID: 20974317
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
